Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.
PET/CT
1 other identifier
observational
66
1 country
1
Brief Summary
The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 4, 2019
CompletedFirst Posted
Study publicly available on registry
September 6, 2019
CompletedStudy Start
First participant enrolled
November 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJune 30, 2022
June 1, 2022
2 years
September 4, 2019
June 26, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
description of bone metastases detected by PET/CT in cancer patients.
Analysis of number, type and SUVmax of metastatic bony lesions detected by PET/CT in cancer patients.
one year
compare diagnostic performance of PET/CT, planar bone scintigraphy and SPECT/CT in detecting bone metastases
compare sensitivity, specificity, PPV,NPV and accuracy
one year
Secondary Outcomes (1)
risk benefit of PET/CT examination in cancer patients
one year
Interventions
18F-fludeoxyglucose positron emission tomography/computed tomography
Eligibility Criteria
This study will recruit patients diagnosed with different types of tumors with wide range of age, suspected or diagnosed to have bone metastases, and referred to nuclear medicine unit to perform PET/CT examination, or resulted in to have bone metastases.
You may qualify if:
- patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do PET/CT examination
- patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during PET/CT examination.
- patients conscious to provide informed consent.
You may not qualify if:
- pregnant women.
- patients with blood sugar \> 200 mg/dL.
- patients unable to sleep in a fixed position for 20 minutes.
- severely ill patients who aren't capable of complying with study procedures or comatose patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut university hospital
Asyut, Egypt
Related Publications (6)
Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011 Apr;7(4):208-18. doi: 10.1038/nrendo.2010.227. Epub 2011 Jan 4.
PMID: 21200394BACKGROUNDChoi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control. 2012 Apr;19(2):102-12. doi: 10.1177/107327481201900204.
PMID: 22487972BACKGROUNDColeman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. doi: 10.1093/annonc/mdu103. Epub 2014 Apr 29.
PMID: 24782453BACKGROUNDCrawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.
PMID: 24411213BACKGROUNDRosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997 Oct 15;80(8 Suppl):1595-607. doi: 10.1002/(sici)1097-0142(19971015)80:8+3.3.co;2-z.
PMID: 9362427BACKGROUNDNational Comprehensive Cancer Network (NCCN) Breast Cancer NCCN Practice Guidelines in Oncology. Fort Washington, PA:NCCN. 2014. Ver. 2.
BACKGROUND
Study Officials
- STUDY CHAIR
Mohamed A. Mekkawy, Prof. Dr
Assiut University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor
Study Record Dates
First Submitted
September 4, 2019
First Posted
September 6, 2019
Study Start
November 1, 2019
Primary Completion
November 1, 2021
Study Completion
December 1, 2021
Last Updated
June 30, 2022
Record last verified: 2022-06